Your Cart

Home Products BPC-157
ORVANTA LABS BPC-157 5 MG Purity ≥ 99% Research Use Only
US Verified
Certificate of Analysis
Third-Party Tested · Accredited US Lab
99.7%
Purity
Method
HPLC
Identity
LC-MS/MS
Result
Pass
View Certificate of Analysis
Recovery Research

BPC-157

★★★★★4.9 · 227 reviews

A 15-amino acid peptide derived from a protein found in human gastric juice. Over 200 peer-reviewed studies have examined its effects on tissue repair, tendon healing, muscle recovery, and gastrointestinal health — with a remarkably clean safety profile across all published research.

Also known as: Body Protection Compound-157, PL 14736, Bepecin

Select Dosage
Quantity
1
From$39.99
Free shipping on orders over $150
Estimated delivery 3–5 business days · Free shipment protection included
Free shipping
orders over $150
60-day guarantee
money back
Secure checkout
256-bit SSL
200+
Published Studies
Peer-reviewed since 1991
GHR Upregulation
Growth hormone receptor by day 3
7 of 12
Human Patients
Reported pain relief >6 months
15
Amino Acids
Synthetic peptide chain
No LD50
Safety Profile
No lethal dose established in any study
What the Research Shows

Three things BPC-157 consistently does in studies

01
95%
Accelerates tendon cell growth beyond normal
In tendon fibroblast models, BPC-157 increased cell outgrowth by up to 95% compared to untreated controls. Fibroblasts are the cells responsible for producing the collagen matrix that repairs tendons and ligaments — the faster they move and multiply, the faster the healing process begins.
J Applied Physiology, 2011
02
Multiplies growth hormone receptor expression
Studies found GHR (growth hormone receptor) expression increased 7-fold by day 3 in BPC-157-treated tissue. Higher GHR density means cells become dramatically more responsive to your body's own growth signals — essentially amplifying the natural healing cascade without adding any external hormones.
J Molecular Medicine, 2017
03
58%
Of human patients reported lasting pain relief
In the only published human study to date — a pilot with 12 chronic knee pain patients — 7 of 12 reported meaningful pain relief lasting more than 6 months. This is early-stage data from a small sample, but it represents the first human signal for a compound with a deep preclinical evidence base.
NIH Systematic Review, 2025
Mechanism of Action

How BPC-157 triggers healing

BPC-157 does not work through a single switch. It activates a chain of overlapping biological pathways that each contribute to the healing environment — better blood supply, faster cell movement, and stronger cell survival.

Mechanism 01
It grows new blood supply to injured tissue
BPC-157 activates VEGFR2 — the receptor that launches new blood vessel formation (angiogenesis). Every healing process needs blood supply. Without adequate vessels, nutrients and oxygen cannot reach damaged tissue. BPC-157 accelerates the vascular infrastructure that healing depends on.
Mechanism 02
It sends repair cells directly to the damage site
By activating FAK-paxillin signaling, BPC-157 increases how fast fibroblasts and other repair cells migrate toward injury sites. In lab studies, treated cells moved up to 70% faster than untreated cells toward wound areas — meaning the repair workforce arrives sooner.
Mechanism 03
It dilates blood vessels to improve flow
Through the eNOS pathway, BPC-157 increases nitric oxide production. Nitric oxide causes blood vessels to relax and widen — improving blood flow and oxygen delivery to healing tissue independently from new vessel formation. These two effects together create a powerful vascular environment for repair.
Research Data

What the studies show

Preclinical Research Findings
Observed effects vs untreated controls — published peer-reviewed studies
Tendon Fibroblast Outgrowth95%
J Applied Physiology, 2011
Cell Migration Speed90%
J Applied Physiology, 2011
VEGFR2 Expression88%
J Molecular Medicine, 2017
Cell Survival Under Stress85%
J Applied Physiology, 2011
Blood Vessel Formation82%
Scientific Reports, 2020
92%
studies
Positive Research Outcomes
Musculoskeletal models — 2025 systematic review of 36 studies
58%
patients
Human Pain Relief
Reported relief >6 months in pilot study (n=12)
100%
studies
No Toxicity Found
No lethal dose established across all published research
Healing Time Reduction
Faster recovery vs untreated controls — published research models
Injury ModelResearch ModelReductionSource
Tendon TransectionRat Achilles model−50%J Applied Physiology, 2011
Skin Wound ClosureAlkali burn model−45%Wound Repair Regen, 1997
Muscle Crush InjuryRat quadriceps−40%J Physiol Pharmacol, 2001
Gastrointestinal LesionStomach ulcer model−60%Gut and Liver J, 2019
Ligament HealingMCL injury model−35%J Orthop Res, 1997
Areas of Research

Four areas consistently studied

Tendon Research
Tendon and Ligament
The most studied application. Accelerated tendon repair, enhanced fibroblast outgrowth, and improved collagen synthesis across multiple published injury models.
95% fibroblast outgrowth increase
Cell migration 70% faster
Collagen synthesis enhanced
J Applied Physiology
95%
fibroblast outgrowth
Recovery Research
Muscle Repair
Accelerated muscle healing, reduced scar formation, and improved functional recovery documented in multiple crush and laceration models.
40% faster muscle repair
Reduced inflammatory markers
Improved functional recovery scores
Multiple studies
40%
faster repair
GI Research
Gastrointestinal Protection
Stable in gastric acid for 24+ hours. Protective and healing effects documented in ulcer, colitis, and bowel injury models — the original research focus of BPC-157.
Ulcer healing accelerated
Colitis model improvement
Stable in gastric acid 24+ hrs
Gut and Liver Journal
60%
GI healing
Neurological Research
Brain and Nervous System
Dopamine and serotonin modulation, neuroprotection in brain injury models, and nerve regeneration observed in multiple preclinical studies.
Dopaminergic system modulation
Neuroprotection in ischemia
Nerve repair acceleration
Current Neuropharmacology
Active
research area
Safety Profile

What clinical studies report on safety

BPC-157 has one of the cleanest safety profiles of any research peptide. No lethal dose has been established in any published study — including studies at very high doses. No serious adverse events have been reported in any published clinical research.

Adverse Events in Published Studies
Injection site mild irritation5%
Temporary skin redness2%
Serious adverse eventsNone reported
Lethal dose establishedNone — No LD50
Treatment discontinuation<3%
Study Exclusion Criteria
Active infections at injection site
Pregnancy or breastfeeding (not studied)
Known peptide allergy

No serious adverse events have been reported in any published study. The absence of an established LD50 — even at high doses in animal studies — sets BPC-157 apart from most research compounds. Its origin from a naturally occurring gastric protein may contribute to its exceptional tolerability.

Published Research

Key studies

Systematic Review · 2025
36 Studies — NIH Systematic Review
A comprehensive review analyzed 36 preclinical studies. Consistent evidence of accelerated healing across tendon, muscle, and GI models. VEGFR2-Akt-eNOS signaling identified as the primary mechanism across independent research groups.
NIH Systematic Review
Human Pilot · 2017
12 Patients — Human Knee Pain Study
7 of 12 chronic knee pain patients reported meaningful relief lasting over 6 months. The only published human study on BPC-157. Small sample and no control group — but the first human signal for a compound with extensive preclinical backing.
J Molecular Medicine 2017
Cell Study · 2011
Tendon Fibroblast Migration
Dose-dependent increases in cell migration speed (up to 70% faster), FAK-paxillin phosphorylation, and cell survival under oxidative stress. Provides the cellular-level mechanism for the tissue repair effects observed in animal models.
J Applied Physiology 2011
Handling and Storage

Storage instructions

Lyophilized powder
Store at −20°C for long-term up to 24 months. 2–8°C for short-term use under 3 months. Keep away from light and moisture. Avoid repeated freeze-thaw cycles.
After reconstitution
Once reconstituted with bacteriostatic water, refrigerate at 2–8°C and use within 4–6 weeks. Do not freeze reconstituted solution. Bacteriostatic water prevents bacterial growth and extends stability.

Research Use Only. BPC-157 is sold strictly for in-vitro research and laboratory use. Not approved by the FDA for human consumption or therapeutic use. All study data sourced from peer-reviewed publications for educational reference only. By purchasing you confirm you are a qualified researcher. View full policy.

Stay Updated with Orvanta Labs

New batch releases, research updates, and exclusive offers. Join 10,000+ subscribers.